Key result
Imipramine-blue reduces Burkitt lymphoma tumor size but does not affect dissemination or angiogenesis.
Why the study?
Current chemotherapeutic regimens for Burkitt lymphoma achieve excellent survival in children but less so in adults, with poor outcomes due to therapy toxicity, tumor lysis syndrome, or CNS metastases. Modulators of reactive oxygen species like the NADPH oxidase 4 inhibitor imipramine-blue are potential treatments needing evaluation.
p-value: p=< 0.05
Imipramine-blue demonstrates potent in vitro and in vivo anti-tumor activity against Burkitt lymphoma and other cancer cell lines without affecting angiogenesis or lymphangiogenesis.
Imipramine-blue reduces experimental Burkitt lymphoma size in CAM xenografts; hypothesis-generating and should not yet inform clinical practice.
Burkitt lymphoma is a rare malignancy arising from B cells. Current chemotherapeutic regimens achieve excellent overall survival rates in children, but less impressive rates in adults. There are cases with poor outcome caused by toxic effects of the therapy, tumor lysis syndrome, or metastatic spread of lymphomas to the central nervous system. Modulators of reactive oxygen species are currently discussed as potential drugs for the treatment of cancer. The NADPH oxidase 4 inhibitor imipramine-blue might satisfy the aforementioned requirements, and was studied here. We used MTT assay, crystal violet assay, and thymidine 3H-incorporation assay to analyze the effects of imipramine-blue on Burkitt lymphoma (BL2, BL2B95, BL30B95, BL41B95), neuroblastoma (KELLY, SH-SY5Y, SMS-KAN), cervix carcinoma (HeLa), breast cancer (MDA-MB231), angiosarcoma (AS-M), human embryonic kidney (HEK293WT), and nonmalignant (FLP1) cell lines. The effects of imipramine-blue on BL2B95 cells in vivo were investigated in xenografts on the chick chorioallantoic membrane (CAM). We report that imipramine-blue is a potent growth inhibitor for several cancer cell lines in vitro with IC(50) values comparable to those of doxorubicin (0.16-7.7 μmol/L). Tumor size of BL2B95 cells inoculated in the CAM was reduced significantly (P < 0.05) after treatment with 10 μmol/L imipramine-blue. Lymphogenic dissemination of BL2B95 and the formation of blood and lymphatic vessels in experimental tumors were not affected. We show that imipramine-blue can be used to decrease the viability of cancer cell lines in vitro and in vivo. Imipramine-blue reduces the size of experimental Burkitt lymphoma significantly but does not affect the dissemination of BL2B95 cells, angiogenesis, and lymphangiogenesis.
No takes yet. Share an insight, caveat, or question.
Klingenberg et al. (2014) studied Burkitt lymphoma and other cancers. Imipramine-blue was evaluated on Tumor size reduction (p=< 0.05). Imipramine-blue significantly reduced the tumor size of BL2B95 Burkitt lymphoma cells inoculated in the chick chorioallantoic membrane (P < 0.05) but did not affect dissemination or angiogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: